Charu Aggarwal, MD, of the Abramson Cancer Center at Penn Medicine, analyzes the findings of clinical reports from ASCO 2017 with a focus on immunotherapy. Topics include the KEYNOTE 24 trial of front-line pembrolizumab for NSCLC; the ARCHER trial of dacomitinib vs. gefitinib in EGFR mutant NSCLC; the ALEX study in ALK rearranged NSCLC; and the CHECKPOINT 32 study of the checkpoint inhibitor combination (nivolumab+ipilimumab) in advanced small cell lung cancer.
Related Links:
Published
November 17, 2017
Created by
BROADCASTMED